Pharmaceuticals

Zevra Therapeutics

Zevra Therapeutics released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 36.22 M (forecast USD 31.96 M), actual EPS USD 0.6 (forecast USD 0.09)

Zevra Therapeutics to release FY2026 Q1 earnings on May 6 After-Market EST, forecast revenue USD 31.96 M, EPS USD 0.0811

Zevra Therapeutics released FY2025 earnings on March 9 After-Market EST, actual revenue USD 106.47 M (forecast USD 100.38 M), actual EPS USD 1.3499 (forecast USD 1.26)

Zevra Therapeutics released FY2025 Q4 earnings on March 9 After-Market (EST), actual revenue USD 34.13M (forecast USD 28.05M), actual EPS USD 0.1948 (forecast USD 0.05)

Zevra Therapeutics to Release FY2025 Q4 Earnings on March 9 After-Market EST, Forecast Revenue USD 28.05 M, EPS USD 0.05

Zevra Therapeutics released FY2025 9 Months Earnings on November 5 After-Market EST, actual revenue USD 72.35 M, actual EPS USD 1.1643

Zevra Therapeutics released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 26.06 M (forecast USD 26.64 M), actual EPS USD -0.01 (forecast USD -0.0337)

Zevra Therapeutics to release FY2025 Q3 earnings on November 5 After-Market EST, forecast revenue USD 26.64 M, EPS USD -0.0337

Zevra Therapeutics CEO Reports Disposition of Common Stock

Zevra Therapeutics released FY2025 Semi-Annual earnings on August 12 After-Market EST, actual revenue USD 46.28 M, actual EPS USD 1.16

Zevra Therapeutics released FY2025 Q2 earnings on August 12 After-Market (EST), actual revenue USD 25.88 M (forecast USD 22.49 M), actual EPS USD 1.2343 (forecast USD 1.6125)

Zevra Therapeutics Inc Expected EPS of $1.50 for Q2 2025

Zevra Therapeutics Announces Q2 2025 Earnings Report

Zevra Therapeutics to Release FY2025 Q2 Earnings on August 12 After-Market EST, Forecast Revenue USD 22.49 M, EPS USD 1.6125

Zevra Therapeutics Publishes Long-term Efficacy and Safety Report on Arimoclomol

Cantor Fitzgerald Raises Zevra Therapeutics EPS Forecast

Zevra Therapeutics to Present NIPLYFFA at Meeting

Zevra Therapeutics Inc. Reports Q1 2025 Earnings

Zevra Therapeutics stock price rises with analysts giving buy rating

HC Wainwright Gives Zevra Buy Rating and Sells FDA Credit

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Micware

Silexion Therapeutics

BiomX

MicroAlgo

MetaVia

Tradr 2X Long XNDU Daily ETF

Vida Global

ZVRA

ARKG

LABU

SBIO

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus rating of "Moderate Buy" from nine research firms. Analysts have set an average price target of $23.33, with one hold and eight buy ratings. Recent upgrades include Guggenheim raising its target to $25 and BTIG initiating coverage with a $23 target. The stock opened at $11.13, with a market cap of $658.01 million. Zevra reported $0.18 EPS for Q2, exceeding estimates, and has a net margin of 101.58%. Institutional investors hold 35.03% of the stock, reflecting growing interest.

Market Beat

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

K Wave Media

Cushman & Wakefield

SEAPEAK LLC 9% CUM RED PERP PREF UNITS SER A

Nano Labs

Annaly Capital Mgmt

Mag Mile Capital, Inc.

Sun Capital Management Corp.

Russell Inv Global Equity ETF

Russell Investment Management LLC

Trinity Capital

TCP Capital

GH Research

Creative Realities

CREATIVE GLOBAL

Capital Asset Planning, Inc.

NVIDIA

K WAVE MEDIA LTD C/WTS 14/05/2030(TO PUR COM)

SEAPEAK LLC 8.5% CUM RED PERP PFD UNTS FXD FLT SER B

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

Trinity Capital Pref Share TRINL 7 01/16/25

TRINITY CAPITAL INC 7.875% NTS 30/09/2029

TRINITY CAPITAL INC 7.875% NOTES DUE 2029

NVIDIA Corporation

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages

Zevra Therapeutics shares are trading lower. The company reported its Q1 financial results.

benzinga_article

Earnings Watch

Zevra Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 36.22 M

Zevra Therapeutics (NASDAQ:ZVRA) is set to announce its Q1 2026 earnings on May 6, with expectations of $0.06 per share and $31.96 million in revenue. The stock recently traded at $9.74, down $0.16, with a market cap of $575.83 million. Analysts have given a consensus rating of "Moderate Buy" with an average target price of $23.00. Insider trading activity includes significant sales by CEO Neil F. Mcfarlane and other insiders. Institutional investors hold 35.03% of the company's stock, reflecting growing interest in the firm.

Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday

Zevra Therapeutics | 10-K: FY2025 Revenue Beats Estimate at USD 106.47 M

IBBQ

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus recommendation of "Moderate Buy" from nine brokerages. Two analysts rated it as hold, while seven issued buy ratings. The average 12-month price target is $23.00. Recent analyst reports include BTIG Research and Guggenheim, both setting a $23.00 target. The stock opened at $10.32, with a market cap of $605.89 million. Insider trading shows a decrease in ownership by key insiders. Institutional investors hold 35.03% of the stock, with recent purchases from various hedge funds.

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Health Care Select Sector SPDR

VG Health

iShares Global Healthcare

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

BTIG analyst Kambiz Yazdi has maintained a Buy rating for Zevra Therapeutics (ZVRA) with a price target of $23.00. Yazdi, a 4-star analyst with a 28.1% average return, focuses on the Healthcare sector. Additionally, Zevra received a Buy rating from TipRanks on April 3, while a Hold rating was reiterated by TipRanks – OpenAI on April 1.

Tip Ranks

BTIG Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

Zevra Therapeutics(ZVRA.US)